YASHWANT S CHAUDHRI
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- SANTEE, CA
- NPI
- 1043258429
- Received
- $17,578 in 321 records, 2019 to 2025 ($14,151 general, $3,426 research)
- As principal investigator
- $1,540,924 of research payments to others in 297 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 75 | $2,360 |
| 2024 | General payment | 42 | $2,886 |
| 2023 | General payment | 33 | $1,002 |
| 2023 | Research payment | 11 | $760 |
| 2022 | General payment | 39 | $4,014 |
| 2021 | General payment | 52 | $1,125 |
| 2020 | General payment | 29 | $793 |
| 2019 | General payment | 21 | $1,969 |
| 2019 | Research payment | 19 | $2,666 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Brainsway USA INC | 1 | $3,112 | 2022 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | $2,666 | 2019 |
| Neuronetics, Inc. | 30 | $2,184 | 2019–2024 |
| Teva Pharmaceuticals USA, Inc. | 46 | $1,921 | 2019–2025 |
| LivaNova USA, Inc. | 8 | $1,570 | 2019 |
| Neurocrine BioSciences, Inc. | 54 | $1,435 | 2021–2025 |
| Janssen Pharmaceuticals, Inc | 38 | $1,194 | 2019–2025 |
| Otsuka America Pharmaceutical, Inc. | 28 | $779 | 2019–2025 |
| Alkermes, Inc. | 25 | $733 | 2019–2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $389 | 2020–2025 |
| ABBVIE INC. | 19 | $369 | 2021–2025 |
| E.R. Squibb & Sons, L.L.C. | 13 | $364 | 2024–2025 |
| Axsome Therapeutics, Inc. | 2 | $143 | 2025 |
| Vanda Pharmaceuticals Inc. | 4 | $126 | 2025 |
| Amgen Inc. | 1 | $122 | 2025 |
| Neurelis, Inc. | 1 | $117 | 2025 |
| Sunovion Pharmaceuticals Inc. | 5 | $90 | 2019–2021 |
| GENZYME CORPORATION | 1 | $76 | 2025 |
| Indivior Inc. | 2 | $47 | 2023–2024 |
| Tempus AI, Inc | 2 | $41 | 2024 |
| Allergan, Inc. | 1 | $29 | 2020 |
| Tris Pharma Inc | 1 | $23 | 2024 |
| Lundbeck LLC | 1 | $19 | 2024 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Food and Beverage | 284 | $8,371 |
| Research payment | 30 | $3,426 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 1 | $3,112 |
| Debt forgiveness | 1 | $1,400 |
| Travel and Lodging | 3 | $1,191 |
| Education | 2 | $76 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-12 | Alkermes, Inc. | $26 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-12-10 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-12-09 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-12-03 | Otsuka America Pharmaceutical, Inc. | $26 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-20 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-19 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $6 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-10 | E.R. Squibb & Sons, L.L.C. | $15 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-11-05 | Otsuka America Pharmaceutical, Inc. | $27 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-28 | Vanda Pharmaceuticals Inc. | $36 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-10-20 | E.R. Squibb & Sons, L.L.C. | $26 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-17 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-10-14 | Otsuka America Pharmaceutical, Inc. | $7 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-07 | Janssen Pharmaceuticals, Inc | $12 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-09-26 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-25 | Janssen Pharmaceuticals, Inc | $26 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-17 | Neurocrine BioSciences, Inc. | $26 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-16 | Otsuka America Pharmaceutical, Inc. | $30 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-12 | E.R. Squibb & Sons, L.L.C. | $13 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-11 | Teva Pharmaceuticals USA, Inc. | $27 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-09-10 | Vanda Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-08 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-09-04 | Janssen Pharmaceuticals, Inc | $92 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-09-02 | Janssen Pharmaceuticals, Inc | $11 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-08-28 | Alkermes, Inc. | $26 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-08-19 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-08-18 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-14 | Teva Pharmaceuticals USA, Inc. | $33 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-08-12 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-07-29 | Otsuka America Pharmaceutical, Inc. | $20 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-07-25 | Janssen Pharmaceuticals, Inc | $22 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-07-25 | Janssen Pharmaceuticals, Inc | $6 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-07-24 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-07-22 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-07-17 | Amgen Inc. | $122 | Food and Beverage | In-kind items and services | UPLIZNA Biological, Inflammation/Rare Disease | 2025 | |
| 2025-07-17 | Neurocrine BioSciences, Inc. | $21 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-07-03 | Axsome Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-06-16 | Alkermes, Inc. | $118 | Food and Beverage | In-kind items and services | LYBALVI Drug, CNS | 2025 | |
| 2025-06-13 | Neurocrine BioSciences, Inc. | $6 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-06-05 | Neurocrine BioSciences, Inc. | $23 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-29 | Neurocrine BioSciences, Inc. | $35 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-22 | Alkermes, Inc. | $14 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-05-21 | Axsome Therapeutics, Inc. | $121 | Food and Beverage | In-kind items and services | Auvelity Drug, Psychology/Psychiatric | 2025 | |
| 2025-05-20 | Otsuka America Pharmaceutical, Inc. | $26 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-05-19 | Alkermes, Inc. | $21 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-05-15 | Alkermes, Inc. | $17 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-05-14 | Teva Pharmaceuticals USA, Inc. | $34 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-05-12 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-07 | Neurocrine BioSciences, Inc. | $26 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-05 | Vanda Pharmaceuticals Inc. | $32 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-04-29 | Otsuka America Pharmaceutical, Inc. | $29 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-04-24 | Janssen Pharmaceuticals, Inc | $145 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-04-24 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-04-24 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $1 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-04-23 | E.R. Squibb & Sons, L.L.C. | $28 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-04-22 | Teva Pharmaceuticals USA, Inc. | $31 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2025 | |
| 2025-04-16 | Janssen Pharmaceuticals, Inc | $28 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-04-15 | Vanda Pharmaceuticals Inc. | $30 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-04-04 | Neurocrine BioSciences, Inc. | $35 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-03-26 | Neurelis, Inc. | $117 | Food and Beverage | In-kind items and services | VALTOCO Drug, EPILEPSY | 2025 | |
| 2025-03-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $26 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-03-06 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-27 | Alkermes, Inc. | $22 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-02-19 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-18 | Neurocrine BioSciences, Inc. | $12 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-13 | E.R. Squibb & Sons, L.L.C. | $20 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-02-11 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-02-06 | GENZYME CORPORATION | $76 | Food and Beverage | In-kind items and services | KEVZARA Biological, Rheumatology | 2025 | |
| 2025-02-04 | Otsuka America Pharmaceutical, Inc. | $19 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-01-31 | Alkermes, Inc. | $23 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2025 | |
| 2025-01-30 | Janssen Pharmaceuticals, Inc | $28 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2025 | |
| 2025-01-23 | E.R. Squibb & Sons, L.L.C. | $24 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Neuroscience | 2025 | |
| 2025-01-17 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2024-12-16 | Janssen Pharmaceuticals, Inc | $11 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2024 | |
| 2024-12-10 | Janssen Pharmaceuticals, Inc | $113 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-12-09 | Otsuka America Pharmaceutical, Inc. | $121 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2024 | |
| 2024-11-26 | Neurocrine BioSciences, Inc. | $30 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-11-25 | E.R. Squibb & Sons, L.L.C. | $132 | Food and Beverage | Cash or cash equivalent | COBENFY Drug, Psychiatry/Psychology | 2024 | |
| 2024-11-20 | Otsuka America Pharmaceutical, Inc. | $28 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2024 | |
| 2024-11-20 | E.R. Squibb & Sons, L.L.C. | $6 | Food and Beverage | Cash or cash equivalent | 2024 | ||
| 2024-11-14 | Neuronetics, Inc. | $1,400 | Debt forgiveness | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2024 | |
| 2024-11-14 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-11-06 | Alkermes, Inc. | $24 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2024 | |
| 2024-10-03 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-10-03 | Teva Pharmaceuticals USA, Inc. | $8 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-09-18 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-08-13 | Neurocrine BioSciences, Inc. | $39 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-08-12 | Tris Pharma Inc | $23 | Food and Beverage | In-kind items and services | Dyanavel XR Drug, ADHD | 2024 | |
| 2024-07-31 | Alkermes, Inc. | $25 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2024 | |
| 2024-07-29 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-29 | Janssen Pharmaceuticals, Inc | $29 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-07-25 | Teva Pharmaceuticals USA, Inc. | $26 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-07-02 | Neurocrine BioSciences, Inc. | $38 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-11 | Neurocrine BioSciences, Inc. | $38 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-11 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-10 | Janssen Pharmaceuticals, Inc | $23 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-06-04 | Teva Pharmaceuticals USA, Inc. | $35 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-06-03 | Alkermes, Inc. | $19 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2024 | |
| 2024-05-20 | Neurocrine BioSciences, Inc. | $37 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-05-13 | Teva Pharmaceuticals USA, Inc. | $37 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-05-13 | Janssen Pharmaceuticals, Inc | $16 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-05-02 | Teva Pharmaceuticals USA, Inc. | $21 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-04-25 | Teva Pharmaceuticals USA, Inc. | $127 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-04-18 | Neurocrine BioSciences, Inc. | $24 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-04-11 | Tempus AI, Inc | $23 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-03-13 | Lundbeck LLC | $19 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-03-06 | Indivior Inc. | $24 | Food and Beverage | In-kind items and services | PERSERIS Drug, BH | 2024 | |
| 2024-02-27 | Neurocrine BioSciences, Inc. | $135 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-02-23 | Janssen Pharmaceuticals, Inc | $24 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2024 | |
| 2024-02-23 | Janssen Pharmaceuticals, Inc | $2 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2024 | |
| 2024-02-05 | Alkermes, Inc. | $14 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2024 | |
| 2024-01-18 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2024 | |
| 2024-01-10 | Teva Pharmaceuticals USA, Inc. | $24 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2024 | |
| 2024-01-08 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-04 | Tempus AI, Inc | $18 | Food and Beverage | In-kind items and services | 2024 | ||
| 2023-12-12 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-12-11 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-11-20 | Teva Pharmaceuticals USA, Inc. | $27 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-11-16 | Teva Pharmaceuticals USA, Inc. | $108 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-11-14 | Teva Pharmaceuticals USA, Inc. | $24 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-11-01 | Teva Pharmaceuticals USA, Inc. | $30 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-10-05 | Otsuka America Pharmaceutical, Inc. | $16 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2023 | |
| 2023-10-04 | Otsuka America Pharmaceutical, Inc. | $19 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-08-30 | Otsuka America Pharmaceutical, Inc. | $9 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-08-29 | Otsuka America Pharmaceutical, Inc. | $1 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-08-22 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2023 | |
| 2023-08-08 | Teva Pharmaceuticals USA, Inc. | $64 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-07-25 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-07-18 | Otsuka America Pharmaceutical, Inc. | $27 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-06-07 | Teva Pharmaceuticals USA, Inc. | $19 | Food and Beverage | In-kind items and services | UZEDY Drug, Neurology | 2023 | |
| 2023-06-06 | Neurocrine BioSciences, Inc. | $15 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-05-12 | Indivior Inc. | $22 | Food and Beverage | In-kind items and services | PERSERIS Drug, BH | 2023 | |
| 2023-05-01 | Alkermes, Inc. | $24 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2023 | |
| 2023-04-28 | Neurocrine BioSciences, Inc. | $12 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-04-28 | Neurocrine BioSciences, Inc. | $3 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-04-12 | Teva Pharmaceuticals USA, Inc. | $15 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2023 | |
| 2023-04-05 | Neurocrine BioSciences, Inc. | $28 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-03-31 | Neurocrine BioSciences, Inc. | $8 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-03-29 | Neurocrine BioSciences, Inc. | $137 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-03-23 | Otsuka America Pharmaceutical, Inc. | $29 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2023 | |
| 2023-03-22 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-03-20 | Teva Pharmaceuticals USA, Inc. | $24 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2023 | |
| 2023-03-02 | Otsuka America Pharmaceutical, Inc. | $120 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-03-01 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-02-22 | Teva Pharmaceuticals USA, Inc. | $44 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-22 | Teva Pharmaceuticals USA, Inc. | $30 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-22 | Teva Pharmaceuticals USA, Inc. | $15 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-21 | Teva Pharmaceuticals USA, Inc. | $140 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-21 | Teva Pharmaceuticals USA, Inc. | $44 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-21 | Teva Pharmaceuticals USA, Inc. | $30 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-21 | Teva Pharmaceuticals USA, Inc. | $15 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-21 | Teva Pharmaceuticals USA, Inc. | $15 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-20 | Teva Pharmaceuticals USA, Inc. | $140 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-20 | Teva Pharmaceuticals USA, Inc. | $38 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-02-19 | Teva Pharmaceuticals USA, Inc. | $246 | Research payment | Cash or cash equivalent | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 | |
| 2023-01-24 | Janssen Pharmaceuticals, Inc | $25 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2023 | |
| 2023-01-19 | Otsuka America Pharmaceutical, Inc. | $19 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2023 | |
| 2023-01-17 | Teva Pharmaceuticals USA, Inc. | $22 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2023 | |
| 2023-01-09 | Janssen Pharmaceuticals, Inc | $23 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2023 | |
| 2022-12-13 | Neurocrine BioSciences, Inc. | $116 | Food and Beverage | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-12-07 | Janssen Pharmaceuticals, Inc | $124 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2022 | |
| 2022-11-21 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2022 | |
| 2022-10-27 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2022 | |
| 2022-10-27 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2022 | |
| 2022-10-24 | Teva Pharmaceuticals USA, Inc. | $13 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2022 | |
| 2022-10-20 | Neuronetics, Inc. | $23 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2022 | |
| 2022-10-10 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2022 | |
| 2022-09-21 | Neurocrine BioSciences, Inc. | $21 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-09-14 | Otsuka America Pharmaceutical, Inc. | $16 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2022 | |
| 2022-09-12 | Neurocrine BioSciences, Inc. | $20 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-08-29 | Teva Pharmaceuticals USA, Inc. | $16 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2022 | |
| 2022-08-08 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-07-29 | Neuronetics, Inc. | $24 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2022 | |
| 2022-07-29 | Neuronetics, Inc. | $24 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2022 | |
| 2022-07-19 | Brainsway USA INC | $3,112 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (5 payments) | Cash or cash equivalent | Brainsway Deep TMS Device, transcranial magnetic stimulation | 2022 | |
| 2022-06-06 | Alkermes, Inc. | $23 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2022 | |
| 2022-05-11 | Neurocrine BioSciences, Inc. | $6 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-05-10 | Teva Pharmaceuticals USA, Inc. | $18 | Food and Beverage | In-kind items and services | AUSTEDO Drug, Central Nervous System | 2022 | |
| 2022-05-09 | Alkermes, Inc. | $23 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2022 | |
| 2022-05-04 | Neurocrine BioSciences, Inc. | $3 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-05-02 | Neurocrine BioSciences, Inc. | $25 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-27 | Janssen Pharmaceuticals, Inc | $24 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2022 | |
| 2022-04-27 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-25 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-25 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-11 | Neurocrine BioSciences, Inc. | $23 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-07 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-04-04 | Alkermes, Inc. | $19 | Food and Beverage | In-kind items and services | ARISTADA Drug, CNS | 2022 | |
| 2022-03-22 | Neurocrine BioSciences, Inc. | $35 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-03-08 | Neurocrine BioSciences, Inc. | $22 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-02-28 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-02-28 | Neurocrine BioSciences, Inc. | $4 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-02-14 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-02-07 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2022 | |
| 2022-02-01 | Neurocrine BioSciences, Inc. | $21 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-01-31 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 | |
| 2022-01-26 | Neurocrine BioSciences, Inc. | $15 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2022 | |
| 2022-01-11 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2022 |
The latest 200 records of 321.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-08-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $7,000 | ITI-007-321 | 2025 |
| 2025-07-31 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $46,800 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2025 |
| 2025-03-03 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $6,757 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-02-19 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,026 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-02-19 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $15,027 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-02-19 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,500 | A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOP | 2025 |
| 2025-01-21 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,170 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2025 |
| 2025-01-07 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,836 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2025 |
| 2024-12-03 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-11-19 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,019 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-11-12 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-10-30 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,019 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-10-15 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,128 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-10-09 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,392 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-09-18 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-09-03 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-08-27 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $7,274 | 67953964MDD3003 | 2024 |
| 2024-08-27 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,395 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-08-13 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,864 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-07-23 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-07-16 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-07-10 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-07-02 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,547 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-07-01 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $270 | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of A | 2024 |
| 2024-06-21 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $2,040 | 67953964MDD3003 | 2024 |
| 2024-06-18 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,240 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-06-06 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,128 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-05-21 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,642 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-05-17 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $4,818 | 67953964MDD3003 | 2024 |
| 2024-05-01 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-04-23 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-04-22 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $2,180 | 67953964MDD3003 | 2024 |
| 2024-04-16 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $376 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-04-15 | Janssen Research & Development, LLC | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $10,922 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-04-12 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,016 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-04-04 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,128 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-03-29 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-26 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,642 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-03-22 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $5,228 | 67953964MDD3003 | 2024 |
| 2024-03-18 | Janssen Research & Development, LLC | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $8,499 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-03-13 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $18,988 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-03-08 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $5,841 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-03-07 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $7,077 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-02-29 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH DBA CMB CLINICAL TRIALS | $4,500 | AMULTICENTER,RANDOMIZED,DOUBLE-BLIND,PLACEBO-CONTROLLED,PARALLEL-ARMSTUDY TOASSESS THEEFFICACY,SAFETY, ANDTOLERABILITY O | 2024 |
| 2024-02-21 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $3,616 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-02-16 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $1,360 | 67953964MDD3003 | 2024 |
| 2024-02-13 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $752 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-02-09 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $14,516 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-02-08 | Janssen Research & Development, LLC | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $23,709 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2024 |
| 2024-02-07 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,642 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-02-07 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $10,408 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-01-31 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $1,181 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-31 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $70 | A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switc | 2024 |
| 2024-01-23 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $4,867 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-17 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $6,216 | 67953964MDD3003 | 2024 |
| 2024-01-16 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $5,164 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-11 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $214,170 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-11 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $53,000 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-10 | Sumitomo Pharma America, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $14,778 | An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in Peop | 2024 |
| 2024-01-09 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $10,210 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2024-01-05 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $15,695 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2024 |
| 2023-12-29 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $70 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-19 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $7,651 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 |
| 2023-12-18 | Janssen Research & Development, LLC | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,254 | A Study of Esketamine Nasal Spray Administered as Monotherapy in Adult Participants With Treatment resistant Depression | 2023 |
| 2023-12-13 | Janssen Research & Development, LLC | California Mntl Behaviour Health, Llc | $3,496 | 67953964MDD3003 | 2023 |
| 2023-12-12 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $10,499 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 |
| 2023-12-08 | Teva Pharmaceuticals USA, Inc. | CALIFORNIA MENTAL BEHAVIORAL HEALTH LLC | $2,163 | A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Lon | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $28 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $17 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $16 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $15 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $14 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $12 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $12 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $11 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $10 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $9 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $7 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $7 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $7 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $5 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $4 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $3 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $3 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $3 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $3 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $3 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $2 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $2 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $2 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $1 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $0 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $0 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $139 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $84 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $84 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $78 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $66 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
| 2023-12-04 | Sumitomo Pharma America, Inc. | CMB CLINICAL TRIALS | $46 | A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Santee, CA, county San Diego County, CA, state California; placed by its city name.
| Measure | Place (city or town) Santee, CA | County San Diego County, CA | State California |
|---|---|---|---|
| Population B01003 | 59,332 | 3,288,774 | 39,287,377 |
| Population, 2020 census P1 | 60,037 | 3,298,634 | 39,538,223 |
| Median age B01002 | 40.3 | 37.3 | 37.9 |
| Under 18 B01001 | 23.1% | 20.9% | 22.0% |
| 65 and over B01001 | 16.5% | 15.4% | 15.7% |
| Households B11001 | 21,196 | 1,171,278 | 13,548,091 |
| Foreign born B05002 | 13.7% | 22.8% | 27.0% |
| Median household income B19013 | $113,394 | $106,268 | $99,122 |
| Median family income B19113 | $127,575 | $122,377 | $113,346 |
| Per capita income B19301 | $49,612 | $51,976 | $49,513 |
| Poverty rate B17001 | 7.9% | 10.3% | 12.0% |
| Unemployment rate B23025 | 4.7% | 6.1% | 6.6% |
| Civilian labor force B23025 | 29,624 | 1,689,384 | 20,068,466 |
| Mean commute (minutes) B08013 | 26.7 | 25.5 | 28.7 |
| Bachelor's degree or higher B15003 | 35.0% | 43.2% | 37.1% |
| Housing units B25001 | 21,851 | 1,250,641 | 14,644,735 |
| Owner-occupied B25003 | 72.4% | 54.6% | 55.9% |
| Renters B25003 | 27.6% | 45.4% | 44.1% |
| Median home value B25077 | $727,200 | $854,700 | $734,700 |
| Median gross rent B25064 | $2,250 | $2,246 | $2,036 |
| White, not Hispanic B03002 | 62.9% | 42.4% | 33.8% |
| Black B03002 | 1.8% | 4.4% | 5.2% |
| Hispanic or Latino B03002 | 20.9% | 34.6% | 40.2% |
| Asian B03002 | 6.5% | 12.1% | 15.3% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Santee, CA.
Comments